Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01416142 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens
A NA study of Myopia, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT01416142: Completed NA study of Myopia, sponsored by Bausch & Lomb Incorporated.
NCT01416142 is a NA study of Myopia that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 63 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01416142, a NA study of Myopia, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the product performance of PureVision2 HD contact lenses.
Primary Outcome
Visual acuity(VA) measured at the screening visit (all eligible participants) while wearing spectacles and the VA measured at the end of study (Visit 3) 1-Week wearing PureVision2 HD lenses. VA wearing spectacles vs. VA wearing PureVision2 HD Lenses, lower the number the better the VA.
Conditions Studied
Interventions
- DEVICE Spectacles
- DEVICE PureVision2 HD contact lenses
Study Locations (1)
New York
- Bausch & Lomb, Inc. - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-09 |
| Phase | NA |
What the finished NCT01416142 record still lists
NCT01416142 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Spectacles is the first listed.
NCT01416142 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01416142 about?
NCT01416142 is a clinical study titled "A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens". The objective of this study is to evaluate the product performance of PureVision2 HD contact lenses.
What is the current status of trial NCT01416142?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2011-07. Estimated completion is 2011-09.
What conditions does trial NCT01416142 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT01416142?
The interventions under investigation include: Spectacles (DEVICE), PureVision2 HD contact lenses (DEVICE).
Who is sponsoring clinical trial NCT01416142?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01416142 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01416142's enrollment target sits among peer trials
63 58th of 90 higher than 32 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia